Click here to view cell apoptosis assay products

Current Position: Home>>SARS-CoV-2>>Tools for research

Tools for research

In late December 2019, a new virulent virus emerged that produced a potentially fatal atypical pneumonia, eventually called COVID-19. Identification and sequencing of the virus responsible for this outbreak determined that it was a novel coronavirus (CoV), which was termed SARS-CoV-2 (2019-nCoV, COVID-19 virus).

With the now global outbreak of COVID-19, SARS-CoV-2 early diagnostics and infection prevention and control has become critical. Elabscience® can provide the following products lines for SARS-CoV-2 (2019-nCoV, COVID-19 virus) research:

Essential Reagents for COVID-19(SARS-CoV-2) IgM/IgG Rapid Test Development

Elabscience® provides essential reagents for development of COVID-19 IgG/IgM Lateral Flow (Rapid Test) assay to help with the qualitative detection of IgG and IgM antibodies specific to SARS-CoV-2 in human biological fluids.

Cat. No. Product Name Size
E-ELC-RTD001 COVID-19 IgG/IgM Rapid Test Development Kit 500-1,000,000 tests
E-ELC-RTD002 COVID-19 IgG/IgM Rapid Test Development Kit(No colloidal gold conjugated) 1,000-100,000 tests
E-ELC-001 Recombinant SARS-CoV-2 N Protein (His Tag) 200μg, 1mg, 5mg, 10mg
E-ELC-002 Recombinant SARS-CoV-2 N Protein (with colloidal gold conjugated) 1mL, 5mL, 10mL
E-ELC-003 Mouse anti-human IgG monoclonal 1mg, 5mg, 10mg
E-ELC-004 Mouse anti-human IgM monoclonal 1mg, 5mg, 10mg
E-ELC-005 Goat anti-chicken IgY polyclonal 1mg, 5mg, 10mg
E-ELC-006 Chicken IgY(with colloidal gold conjugated) 1mL, 5mL, 10mL
E-ELC-008 Buffer for Rapid Test Development(02) 1,000, 5,000, 10,000 tests
E-ELC-009 Chicken IgY 1mg, 5mg, 10mg

10 Minutes Rapid Detection of COVID-19 (SARS-CoV-2) IgM/IgG (GICA)

This kit is a  lateral flow devices for the qualitative detection of IgG and IgM antibodies to the coronavirus in human whole blood, serum or plasma. It is a  rapid chromatographic immunoassay with advantages of easy to use and provide rapid results within 10 minutes.

VIEW PRODUCT

covid_pic1

SARS-CoV-2 Host Associated Proteins

Coronaviruses have four structural proteins (E,M,N,S protein) that can bind to membrane receptors on host cells, thereby mediating the fusion of the virus and the cell membrane. After the S protein of SARS-CoV-2 interacts with ACE2 and then enters the cell through endocytosis, Cathepsin B/L degrades the Spike protein to release nucleic acids of virus. In addition, CD147 also plays a functional role in promoting SARS-CoV-2 invasion into host cells.

Cat. No. Product Name Purity Accession
PKSH032068 Recombinant Human ACE2 Protein (His Tag) > 95 % Q9BYF1
PKSH032179 Recombinant Human Cathepsin B/CTSB Protein (His Tag) > 95 % P07858
PKSM040956 Recombinant Mouse Cathepsin B/CTSB Protein (His Tag) > 95 % P10605
PKSH032182 Recombinant Human Cathepsin L/CTSL Protein (His Tag) > 95 % P07711
PKSM041247 Recombinant Mouse Cathepsin L/CTSL Protein (aa 18-334, His Tag) > 95 % P06797
PKSH032377 Recombinant Human CD147/Basigin Protein (His Tag) > 95 % P35613-2
PKSM041223 Recombinant Mouse CD147/Basigin Protein (His Tag) > 90 % NP_001070652.1

ELISA Kits for SARS-CoV-2 Antigen/Antibody Detection

Elabscience® newly developed ELISA kits for SARS-CoV-2 antigen/antibody determination. These kits are mainly specific to the most important structural proteins, the spike protein and nucleocapsid protein.

Application Target Cat.NO. Product Name
COVID-19 Antibody Qualitative Determination N protein E-EL-E600 SARS-CoV-2 Nucleocapsid Protein IgG ELISA Kit
E-EL-E601 SARS-CoV-2 Nucleocapsid Protein IgM ELISA Kit
E-EL-E606 SARS-CoV-2 Neutralization Antibody ELISA Kit
S protein E-EL-E602 SARS-CoV-2 Spike Protein IgG ELISA Kit
E-EL-E603 SARS-CoV-2 Spike Protein IgM ELISA Kit
E-EL-E607 SARS-CoV-2 Spike Protein Total Antibody ELISA Kit
COVID-19 Antigen Quantitative Determination N protein E-EL-E604 SARS-CoV-2 Nucleocapsid Protein ELISA Kit
S protein E-EL-E605 SARS-CoV-2 Spike Protein S1 RBD ELISA Kit

ELISA Kits for Monitoring the Cytokine Storm

Accumulating research evidence indicates that many patients with severe COVID-19 might have a cytokine storm syndrome, and this suggests that people with severe COVID-19 or suspicious COVID-19 infection should be monitored for hyperinflammation.

Cat. No. Target Reactivity
E-EL-H0102 IL-6 Human
E-EL-H6008 IL-8 Human
E-EL-H0149 IL-1β Human
E-EL-H0109 TNFα Human
E-EL-H0108 IFNγ Human
E-EL-H6005 MCP1 Human
E-EL-0162 TGF-β1 Universal
E-EL-H0043 CRP Human

SARS-CoV-2(2019-nCoV) Antibodies

Since the SARS-CoV-2-Spike protein and Nucleocapsid Protein (NP) are the biomarkers of 2019-nCoV, and angiotensin convertenzyme 2 (ACE-2) is the main surface receptor to SARS-CoV-2 , it is important to fully understand the role these proteins play in SARS-CoV-2 infection. Elabsicnece® offers a variety of antibodies to investigate the mechanisms of the SARS-CoV-2 life cycle.

Classification Cat. No. Product Name Applications
2019-nCoV Spike Antibody E-AB-V1001 SARS-COV-2 Spike Monoclonal Antibody(2019-nCoV) ELISA
E-AB-V1002 SARS-COV-2 Spike Monoclonal Antibody(2019-nCoV) ELISA
E-AB-V1003 SARS-COV-2 Spike Monoclonal Antibody(2019-nCoV) IF,ELISA
E-AB-V1005 SARS-COV-2 Spike S1 Monoclonal Antibody(2019-nCoV) IF,ELISA
E-AB-V1006 SARS-COV-2 Spike RBD Polyoclonal Antibody(2019-nCoV) WB,ELISA
E-AB-V1007 SARS-COV-2 Spike Monoclonal Antibody(IgG / IgM Positive Control) ELISA
E-AB-V1008 SARS-COV-2 Spike Monoclonal Antibody(2019-nCoV) ELISA
E-AB-V1009 SARS-COV-2 Spike S2 Monoclonal Antibody(2019-nCoV) ELISA
E-AB-V1010 SARS-COV-2 Spike S2 Polyclonal Antibody(2019-nCoV) ELISA
2019-nCoV Spike Neutralizing Antibody E-AB-V1021 Anti-2019-nCoV S-hIgG1 Neutralizing Antibody Neutralization, ELISA
E-AB-V1022 Anti-2019-nCoV S-mIgG1 Neutralizing Antibody Neutralization, ELISA
E-AB-V1023 Anti-2019-nCoV S-cIgG1 Neutralizing Antibody Neutralization, ELISA
E-AB-V1024 Anti-2019-nCoV Spike Neutralizing Antibody Neutralization, ELISA
E-AB-V1025 Anti-2019-nCoV Spike Neutralizing Antibody Neutralization, ELISA
E-AB-V1026 Anti-2019-nCoV S-IgM Neutralizing Antibody Neutralization, ELISA
E-AB-V1027 Anti-2019-nCoV S-IgA Neutralizing Antibody Neutralization, ELISA
E-AB-V1028 Anti-SARS-CoV-2 Spike RBD (CB6 biosimilar) Neutralizing Antibody Neutralization, ELISA
2019-nCoV Nucleocapsid Protein Antibody E-AB-V1011 SARS-COV-2 NP Monoclonal Antibody(2019-nCoV) ELISA
E-AB-V1012 SARS-COV-2 NP ScFv Monoclonal Antibody(2019-nCoV) ELISA
E-AB-V1013 SARS-COV-2 NP Monoclonal Antibody(2019-nCoV) WB,ELISA
E-AB-V1014 SARS-COV-2 NP Monoclonal Antibody(2019-nCoV) WB,ELISA
E-AB-V1015 SARS-COV-2 NP Polyclonal Antibody(2019-nCoV) WB,ELISA
E-AB-V1016 SARS-COV-2 NP Polyclonal Antibody(2019-nCoV) ELISA
E-AB-V1017 SARS-COV-2 NP Monclonal Antibody(IgG / IgM Positive Control) ELISA
E-AB-V1018 SARS-COV-2 NP Monoclonal Antibody(2019-nCoV) ELISA
ACE2 Antibody E-AB-12224 ACE2 Polyclonal Antibody IHC,ELISA
E-AB-70126 ACE2 Polyclonal Antibody WB,ELISA
Related Secondary Antibody E-AB-1001 Goat Anti-Mouse IgG(H+L)(peroxidase/HRP conjugated) WB,IHC,ELISA
E-AB-1003 Goat Anti-Rabbit IgG (H+L)(peroxidase/HRP conjugated) WB,IHC,ELISA
E-AB-1006 Rabbit Anti-Human IgG(H+L)(peroxidase/HRP conjugated) WB,ELISA

Cell Line for the Research of SARS-CoV-2

Current events around the spread of COVID-19 (SARS-CoV-2) and its impact on public health continue to evolve. Researchers all over the world are committed to the development of COVID-19 vaccine and the development of drugs. In vitro experiments using cell lines for drug screening can greatly improve the speed of screening anti-SARS-CoV-2 drugs.

Cell Line Species
VERO C1008 [Vero E6] cell line Cercopithecus aethiops
Vero Cell Line Cercopithecus aethiops
Calu-3 Cell Line Homo sapiens, Human
HuH-7 Cell Line Homo sapiens, Human
Caco-2 Cell Line Homo sapiens, Human
293T [HEK-293T] Cell Line Homo sapiens, Human
LLC-MK2 cell line Macaca mulatta, Monkey, Rhesus

Custom Peptides Service

In the researches of coronavirus COVID-19, customized peptides can also be offered. Elabscience® offers synthesis service of different quality and purity range.

VIEW MORE

References

1. Zhang, Y.-Z. & Holmes, E. C. A Genomic Perspective on the Origin and Emergence of SARS-CoV-2. Cell 0, (2020)

2. Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell (2020)

3. Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 1–12 (2020)

4. Lan, J. et al. Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. Nature 1–20 (2020)

5. Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 1–8 (2020)

6. Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020)

7. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020)

8. Lam, T. T.-Y. et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature 1–6 (2020)

9. Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020)

10. Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. (2020)

11. Xu, Y. et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat. Med. 1–4 (2020)

12. Yan, R. et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science (2020)

Apply for
*Product Name:
*Catalog Number:
*Name:
*Email:
*Message:
*Country:
*When will you use it?

*Captcha: